• Citer

Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

par Albshesh, Ahmad;Taylor, Joshua;Savarino, Edoardo;Truyens, Marie;Armuzzi, Alessandro;Ribaldone, Davide;Bar-Gil Shitrit, Ariella;Fibelman, Morine;Molander, Pauliina;Liefferinckx, Claire ;Nancey, Stéphane;Korani, Mohamed;Rutka, Mariann;Barreiro-de Acosta, Manuel;Domislovic, Viktor;Suris, Gerard;Eriksson, C;Alves, Catarina;Mpitouli, Afroditi;di Jiang, Caroline;Tepeš, Katja;Coletta, Marina;Foteinogiannopoulou, Kalliopi;Gisbert, Javier J.P.;Amir-Barak, Hadar;Attauabi, Mohamed;Seidelin, Jakob;Afif, Waqqas;Marinelli, Carla;Lobaton, Triana;Pugliese, Daniela;Maharshak, Nitsan;Cremer, Anneline ;Limdi, Jimmy;Molnar, Tamas;Otero-Alvarin, Borja;Krznaric, Zeljko;Magro, Fernando;Karmiris, Konstantinos;Raine, Tim;Drobne, David;Koutroubakis, Ioannis;Chaparro, Maria;Yanai, Henit;Burisch, J.;Kopylov, Uri
Référence Journal of Clinical Medicine, 10, 13, page (2914)
Publication Publié, 2021-07-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.